



**ASX Announcement | 11 February 2020
Althea Group Holdings (ASX:AGH)**

Strong patient growth in January

Investment Highlights:

- 572 new patients were added in January
- 4,590 Australian patients had been prescribed Althea’s medicinal cannabis products by 459 Healthcare Professionals, as at 31 January 2020
- The Australian medicinal cannabis market increased at its fourth highest rate in January, adding 3,151 TGA SAS Category B approvals¹


11 February 2020: **Australian pharmaceutical company Althea Group Holdings Limited (ASX:AGH) (‘Althea’ or ‘the Company’)** is pleased to provide the following market update with regards to the uptake of its medicinal cannabis products in Australia for the month of January 2020.

January second-best month on record

January ended as the second-best month on record for Althea, with 572 new patients added, highlighting the strong demand from new patients for Althea’s medicines.


As at 31 January 2020, 4,590 Australian patients had been prescribed Althea’s medicinal cannabis products by 459 Healthcare Professionals (‘HCP’s’).

Chart 1: Patient growth as at 31 January 2019



¹ <https://www.tga.gov.au/access-medicinal-cannabis-products-1>


Chart 2: HCP growth as at 31 January 2020



Medicinal cannabis application approvals

Althea’s growth has been supported by the increase in Therapeutic Good Administration (‘TGA’) Special Access Scheme Category B (‘SAS B’) application approvals in Australia. The Australian medicinal cannabis market increased at its fourth highest rate in January, adding 3,151 TGA SAS Category B approvals².

Chart 3: SAS B growth as at 31 January 2020



² <https://www.tga.gov.au/access-medicinal-cannabis-products-1>



Althea CEO Josh Fegan said: “We are unrelenting in our efforts to grow the number of patients utilising Althea products and there is no question that our patient growth in January was better than expected, given that many doctors take time off to spend the summer holidays with their families. Althea is incredibly fortunate to have *Althea Concierge*, our proprietary online prescribing platform, which is able to service doctors and patients 24/7 with all their medicinal cannabis needs, as well as our high performance on the ground sales team. The acceleration in patient numbers experienced over December and January is also continuing into February.”

-ENDS-

Authorised by: Robert Meissner, Company Secretary

For further information, please contact:

Althea

Josh Fegan

CEO & Managing Director

M: 1300 70 20 20

E: contact@althea.life

Media Enquiries

Kirby Symes

Media Relations

P: +613 9650 5096

E: ksymes@althea.life

Althea Group Holdings Limited (ASX:AGH)

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of products, education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into Germany, emerging markets throughout Asia and other parts of Europe.

To learn more, please visit: www.althea.life